On March 17, 2026 Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, reported that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted as a poster presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026 taking place from April 17 to 22, 2026 in San Diego, CA as detailed below. AACR (Free AACR Whitepaper) has announced that it will release further details for clinical trial abstracts for the conference on April 17, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presenter Abstract Title Presentation Details
Thorvardur Halfdanarson, Mayo Clinic Comprehensive Cancer Center [212Pb]VMT-a-NET in advanced SSTR2+ neuroendocrine tumors: safety and preliminary efficacy results from dose-finding cohorts 1, 2 and 3 Abstract Number: CT088
Session Type: Poster presentation
Session Title: Phase I Clinical Trials in Progress
Session Date: April 20, 2026
Session Time: 9:00 am – 12:00 pm
About [212Pb]VMT-α-NET
Perspective designed [212Pb]VMT-α-NET to target and deliver 212Pb to tumor sites expressing somatostatin receptor type 2 (SSTR2). The Company is conducting a multi-center, open-label, dose-escalation, dose-expansion study (clinicaltrials.gov identifier NCT05636618) of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not received prior radiopharmaceutical therapies (RPT).

Interim analysis with a data cut-off date of December 10, 2025 was previously reported at the 2026 ASCO (Free ASCO Whitepaper) Gastrointestinal Cancers Symposium (ASCO-GI) in January 2026, including efficacy data on half of the patients in Cohort 2 and both patients in Cohort 1. Initial efficacy data for the remaining patients in Cohort 2 and eight patients in Cohort 3 are pending, and submissions for presentations at additional medical conferences during 2026 are planned.

Highlights from the previously presented ASCO (Free ASCO Whitepaper)-GI analysis included the following:

Safety findings based on 56 patients who received at least one treatment:

The 56 patients in this safety analysis comprised 2 patients in Cohort 1 (2.5 mCi), 46 patients in Cohort 2 (5.0 mCi), and 8 patients in Cohort 3 (6.0 mCi).
There were no reports of dose limiting toxicities (DLTs), treatment-related discontinuations, serious renal complications, dysphagia, or clinically significant treatment-related myelosuppression.
Grade 3 or higher treatment-emergent adverse events were reported in 21 patients (37.5%). One of these patients, who was enrolled in Cohort 3, experienced a transient Grade 4 event (lymphocyte count decrease). This event was transient and resolved without medical intervention. The patient continues to receive [212Pb]VMT-α-NET treatment. There were no Grade 5 events.
Serious adverse events were reported in 5 patients, with none deemed related to the study medication.
Anti-tumor activity based on both patients in Cohort 1 and 23 (half) of the patients enrolled in Cohort 2:

Updated efficacy analysis in the same 25 patients from ESMO (Free ESMO Whitepaper) Congress 2025 (ESMO 2025) in October 2025 was presented with an additional ~13 weeks of follow-up since the previous presentation at ESMO (Free ESMO Whitepaper) 2025.
19 of the 25 patients (76%) were without progression and remained alive, including both patients in Cohort 1.
Nine (39%) patients in Cohort 2 were observed to have response according to investigator-assessed RECIST v1.1. Eight (35%) of those responses were confirmed and previously reported at ESMO (Free ESMO Whitepaper) 2025. One additional patient experienced an initial response in their most recent tumor assessment after the prior update at ESMO (Free ESMO Whitepaper) 2025. As the patient remains on study, the patient is expected to receive a subsequent tumor assessment.
Seven patients were observed to have deepening of best response, including one patient with stable disease.

(Press release, Perspective Therapeutics, MAR 17, 2026, View Source [SID1234663663])